Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

被引:5
作者
Lu, Yu-Xia [1 ]
Chang, Yi-Zhong [1 ]
Liang, Ping [2 ]
Yang, Chang-Qing [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Inst Digest Dis, Dept Infect Dis,Dept Gastroenterol & Hepatol,Sch, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Lab Med, Sch Med, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic viral hepatitis B; Clostridium butyricum; Entecavir; Intestinal microflora; GUT-LIVER AXIS; MICROBIOTA; CIRRHOSIS; PATHOGENESIS; DISEASES;
D O I
10.1007/s40121-021-00463-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction To explore the influence of intestinal flora on the occurrence, development and antiviral therapy of chronic hepatitis B (CHB), 16S rDNA amplification sequencing was performed to investigate the intestinal flora in CHB patients treated with entecavir (ETV) and Clostridium butyricum (CB). Methods CHB patients were divided into the ETV group (treatment with ETV alone) and ETV + CB group (treatment with ETV and CB). After 8-week treatment, feces samples were collected and processed for 16S rDNA amplicon sequencing; blood samples were collected for the biochemical, immunologic and virologic evaluations, which were compared between groups. Results ETV treatment for 8 weeks significantly decreased the serum levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor-alpha (TNF-alpha) and HBV DNA compared to those before treatment, but there were no marked differences between the ETV group and ETV + CB group. The intestinal flora changed significantly in the CHB patients after ETV + CB treatment: there were marked differences in 13 unique species before treatment and 4 unique species after ETV + CB treatment; at the phylum level, the top five bacteria with significant difference between patients before treatment and ETV + CB patients were Firmicutes, Actinobacteria, Cyanobacteria, Euryarchaeota and Synergistetes. There were significant differences in 25 unique species in the ETV group and 4 unique species in the ETV + CB group; at the phylum level, the top five bacteria with significant difference between ETV patients and ETV + CB patients were Actinobacteria, Fusobacteria, Proteobacteria, Saccharibacteria and Synergistetes. Conclusion ETV treatment improves the serum biochemical, immunologic and virologic variables, but additional CB fails to further improve these variables. Of note, additional CB affects the intestinal flora in the CHB patients treated with ETV.
引用
收藏
页码:1519 / 1530
页数:12
相关论文
共 50 条
  • [41] Tenofovir is Superior to Entecavir in Patients with Treatment-naive Hepatitis B e-Antigen-Positive Chronic Hepatitis B
    Behera, Manas K.
    Pati, Girish K.
    Narayan, Jimmy
    Mishra, Debakanta
    Meher, Lalit K.
    Singh, Ayaskant
    Uthansingh, Kanishka
    Sahu, Manoj K.
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 11 (01) : 37 - 44
  • [42] Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
    Papatheodoridis, George V.
    Dalekos, George N.
    Yurdaydin, Cihan
    Buti, Maria
    Goulis, John
    Arends, Pauline
    Sypsa, Vana
    Manolakopoulos, Spilios
    Mangia, Giampaolo
    Gatselis, Nikolaos
    Keskin, Onur
    Savvidou, Savvoula
    Hansen, Bettina E.
    Papaioannou, Christos
    Galanis, Kostantinos
    Idilman, Ramazan
    Colombo, Massimo
    Esteban, Rafael
    Janssen, Harry L. A.
    Lampertico, Pietro
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 (02) : 363 - 370
  • [43] Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
    Lee, Sung Won
    Choi, Jonggi
    Kim, Seung Up
    Lim, Young-Suk
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (03) : 402 - 412
  • [44] The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B
    Kose, Sukran
    Tatar, Bengu
    Gul, Selma
    Pala, Emel
    [J]. ACTA CLINICA BELGICA, 2016, 71 (04) : 244 - 249
  • [45] Colonization of Clostridium butyricum in Rats and Its Effect on Intestinal Microbial Composition
    Luo, Xianshu
    Kong, Qing
    Wang, Yuming
    Duan, Xuefeng
    Wang, Peng
    Li, Chenman
    Huan, Yuchen
    [J]. MICROORGANISMS, 2021, 9 (08)
  • [46] Safety of entecavir antiviral therapyduring an accidental pregnancy in patients with chronic hepatitis B
    Cao, Lihua
    Li, Shiwu
    Dong, Jingchao
    Wen, Jingkui
    Ding, Lina
    Ge, Yahui
    Yang, Qing
    Xu, Xiaoyuan
    Zhuang, Hui
    [J]. BIOMEDICAL REPORTS, 2023, 19 (04)
  • [47] Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Guangbi Yao
    Xiaqiu Zhou
    Daozheng Xu
    Baoen Wang
    Hong Ren
    Jessica Liu
    Dong Xu
    Laurie MacDonald
    [J]. Hepatology International, 2007, 1 : 373 - 381
  • [48] Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China
    Yao, Guangbi
    Zhou, Xiaqiu
    Xu, Daozheng
    Wang, Baoen
    Ren, Hong
    Liu, Jessica
    Xu, Dong
    MacDonald, Laurie
    [J]. HEPATOLOGY INTERNATIONAL, 2007, 1 (03) : 373 - 381
  • [49] Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation
    Hsu, Yao-Chun
    Mo, Lein-Ray
    Chang, Chi-Yang
    Perng, Daw-Shyong
    Tseng, Cheng-Hao
    Lo, Gin-Ho
    Tai, Chih-Min
    Lin, Chih-Wen
    Hsu, Chia-Chang
    Hsu, Chuan-Yuan
    Huang, Shih-Che
    Lin, Jaw-Town
    [J]. ANTIVIRAL THERAPY, 2012, 17 (04) : 605 - 612
  • [50] Comparable outcomes of decompensated chronic hepatitis B patients treated with entecavir or tenofovir: an 8-year cohort study
    Lee, Kuan-Chieh
    Cheng, Jur-Shan
    Chang, Ming-Ling
    Chien, Rong-Nan
    Liaw, Yun-Fan
    [J]. HEPATOLOGY INTERNATIONAL, 2022, 16 (04) : 799 - 806